{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,29]],"date-time":"2026-03-29T13:35:49Z","timestamp":1774791349307,"version":"3.50.1"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2020,1,9]],"date-time":"2020-01-09T00:00:00Z","timestamp":1578528000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,1,9]],"date-time":"2020-01-09T00:00:00Z","timestamp":1578528000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Differ"],"published-print":{"date-parts":[[2020,7]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Cutaneous malignant melanoma (CMM) is the deadliest form of skin cancer and clinically challenging due to its propensity to develop therapy resistance. Reactive oxygen species (ROS) can induce DNA damage and play a significant role in CMM. MTH1 protein protects from ROS damage and is often overexpressed in different cancer types including CMM. Herein, we report that MTH1 inhibitor TH1579 induced ROS levels, increased DNA damage responses, caused mitotic arrest and suppressed CMM proliferation leading to cell death both in vitro and in an in vivo xenograft CMM zebrafish disease model. TH1579 was more potent in abrogating cell proliferation and inducing cell death in a heterogeneous co-culture setting when compared with CMM standard treatments, vemurafenib or trametinib, showing its broad anticancer activity. Silencing MTH1 alone exhibited similar cytotoxic effects with concomitant induction of mitotic arrest and ROS induction culminating in cell death in most CMM cell lines tested, further emphasizing the importance of MTH1 in CMM cells. Furthermore, overexpression of receptor tyrosine kinase AXL, previously demonstrated to contribute to BRAF inhibitor resistance, sensitized <jats:italic>BRAF<\/jats:italic> mutant and <jats:italic>BRAF\/NRAS<\/jats:italic> wildtype CMM cells to TH1579. AXL overexpression culminated in increased ROS levels in CMM cells. Moreover, silencing of a protein that has shown opposing effects on cell proliferation, CAV-1, decreased sensitivity to TH1579 in a BRAF inhibitor resistant cell line. AXL-MTH1 and CAV-1-MTH1 mRNA expressions were correlated as seen in CMM clinical samples. Finally, TH1579 in combination with BRAF inhibitor exhibited a more potent cell killing effect in <jats:italic>BRAF<\/jats:italic> mutant cells both in vitro and in vivo. In summary, we show that TH1579-mediated efficacy is independent of <jats:italic>BRAF\/NRAS<\/jats:italic> mutational status but dependent on the expression of AXL and CAV-1.<\/jats:p>","DOI":"10.1038\/s41418-019-0488-1","type":"journal-article","created":{"date-parts":[[2020,1,9]],"date-time":"2020-01-09T16:02:33Z","timestamp":1578585753000},"page":"2081-2098","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["AXL and CAV-1 play a role for MTH1 inhibitor TH1579 sensitivity in cutaneous malignant melanoma"],"prefix":"10.1038","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2019-8072","authenticated-orcid":false,"given":"Ishani","family":"Das","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helge","family":"Gad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lars","family":"Br\u00e4utigam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Linda","family":"Pudelko","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rainer","family":"Tuominen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Veronica","family":"H\u00f6iom","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ingrid","family":"Alml\u00f6f","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Varshni","family":"Rajagopal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johan","family":"Hansson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Helleday","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0524-2346","authenticated-orcid":false,"given":"Suzanne","family":"Egyh\u00e1zi Brage","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6372-1396","authenticated-orcid":false,"given":"Ulrika","family":"Warpman Berglund","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,1,9]]},"reference":[{"key":"488_CR1","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/S0140-6736(18)31559-9","volume":"392","author":"D Schadendorf","year":"2018","unstructured":"Schadendorf D, van Akkooi ACJ, Berking C, Griewank KG, Gutzmer R, Hauschild A, et al. Melanoma. Lancet. 2018;392:971\u201384.","journal-title":"Lancet."},{"key":"488_CR2","doi-asserted-by":"crossref","first-page":"E157","DOI":"10.3390\/cancers10060157","volume":"10","author":"AX Torres-Collado","year":"2018","unstructured":"Torres-Collado AX, Knott J, Jazirehi AR. Reversal of resistance in targeted therapy of metastatic melanoma: lessons learned from vemurafenib (BRAF(V600E)-specific inhibitor). Cancers. 2018;10:E157.","journal-title":"Cancers"},{"key":"488_CR3","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1200\/JCO.2017.72.2850","volume":"36","author":"MK Callahan","year":"2018","unstructured":"Callahan MK, Kluger H, Postow MA, Segal NH, Lesokhin A, Atkins MB, et al. Nivolumab plus ipilimumab in patients with advanced melanoma: updated survival, response, and safety data in a phase I dose-escalation study. J Clin Oncol. 2018;36:391\u20138.","journal-title":"J Clin Oncol"},{"key":"488_CR4","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/j.cell.2017.01.017","volume":"168","author":"P Sharma","year":"2017","unstructured":"Sharma P, Hu-Lieskovan S, Wargo JA, Ribas A. Primary, adaptive, and acquired resistance to cancer immunotherapy. Cell 2017;168:707\u201323.","journal-title":"Cell"},{"key":"488_CR5","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1007\/978-3-540-37696-5_16","volume":"174","author":"FL Meyskens Jr.","year":"2007","unstructured":"Meyskens FL Jr., Farmer PJ, Yang S, Anton-Culver H. New perspectives on melanoma pathogenesis and chemoprevention. Recent Results Cancer Res. 2007;174:191\u20135.","journal-title":"Recent Results Cancer Res"},{"key":"488_CR6","doi-asserted-by":"crossref","DOI":"10.1186\/s12943-017-0667-y","volume":"16","author":"G Cesi","year":"2017","unstructured":"Cesi G, Walbrecq G, Zimmer A, Kreis S, Haan C. ROS production induced by BRAF inhibitor treatment rewires metabolic processes affecting cell growth of melanoma cells. Mol Cancer. 2017;16:102.","journal-title":"Mol Cancer."},{"key":"488_CR7","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1016\/j.cell.2018.04.012","volume":"173","author":"L Wang","year":"2018","unstructured":"Wang L, Leite de Oliveira R, Huijberts S, Bosdriesz E, Pencheva N, Brunen D, et al. An acquired vulnerability of drug-resistant melanoma with therapeutic potential. Cell. 2018;173:1413\u201325 e14.","journal-title":"Cell."},{"key":"488_CR8","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/1477-3163-5-14","volume":"5","author":"G Waris","year":"2006","unstructured":"Waris G, Ahsan H. Reactive oxygen species: role in the development of cancer and various chronic conditions. J Carcinog. 2006;5:14.","journal-title":"J Carcinog."},{"key":"488_CR9","doi-asserted-by":"crossref","first-page":"117727191875539","DOI":"10.1177\/1177271918755391","volume":"13","author":"S Kumari","year":"2018","unstructured":"Kumari S, Badana AK, G MM, G S, Malla R. Reactive Oxygen Species: A Key Constituent in Cancer Survival. Biomark Insights. 2018;13:1177271918755391.","journal-title":"Biomark Insights"},{"key":"488_CR10","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1016\/j.molcel.2018.03.029","volume":"70","author":"CK Tsang","year":"2018","unstructured":"Tsang CK, Chen M, Cheng X, Qi Y, Chen Y, Das I, et al. SOD1 phosphorylation by mTORC1 couples nutrient sensing and redox regulation. Mol Cell. 2018;70:502\u201315 e8.","journal-title":"Mol Cell."},{"key":"488_CR11","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.freeradbiomed.2011.09.035","volume":"52","author":"B Vurusaner","year":"2012","unstructured":"Vurusaner B, Poli G, Basaga H. Tumor suppressor genes and ROS: complex networks of interactions. Free Radic Biol Med. 2012;52:7\u201318.","journal-title":"Free Radic Biol Med"},{"key":"488_CR12","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.freeradbiomed.2016.11.002","volume":"107","author":"Y Nakabeppu","year":"2017","unstructured":"Nakabeppu Y, Ohta E, Abolhassani N. MTH1 as a nucleotide pool sanitizing enzyme: friend or foe? Free Radic Biol Med. 2017;107:151\u20138.","journal-title":"Free Radic Biol Med"},{"key":"488_CR13","doi-asserted-by":"crossref","first-page":"84671","DOI":"10.18632\/oncotarget.19404","volume":"8","author":"L Pudelko","year":"2017","unstructured":"Pudelko L, Rouhi P, Sanjiv K, Gad H, Kalderen C, Hoglund A, et al. Glioblastoma and glioblastoma stem cells are dependent on functional MTH1. Oncotarget. 2017;8:84671\u201384.","journal-title":"Oncotarget."},{"key":"488_CR14","doi-asserted-by":"crossref","first-page":"2366","DOI":"10.1158\/0008-5472.CAN-15-2380","volume":"76","author":"L Brautigam","year":"2016","unstructured":"Brautigam L, Pudelko L, Jemth AS, Gad H, Narwal M, Gustafsson R, et al. Hypoxic signaling and the cellular redox tumor environment determine sensitivity to MTH1 inhibition. Cancer Res. 2016;76:2366\u201375.","journal-title":"Cancer Res."},{"key":"488_CR15","doi-asserted-by":"crossref","first-page":"6226","DOI":"10.1158\/0008-5472.CAN-17-1965","volume":"77","author":"JY Wang","year":"2017","unstructured":"Wang JY, Liu GZ, Wilmott JS, La T, Feng YC, Yari H, et al. Skp2-mediated stabilization of MTH1 promotes survival of melanoma cells upon oxidative stress. Cancer Res. 2017;77:6226\u201339.","journal-title":"Cancer Res."},{"key":"488_CR16","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/nature13181","volume":"508","author":"H Gad","year":"2014","unstructured":"Gad H, Koolmeister T, Jemth AS, Eshtad S, Jacques SA, Strom CE, et al. MTH1 inhibition eradicates cancer by preventing sanitation of the dNTP pool. Nature. 2014;508:215\u201321.","journal-title":"Nature."},{"key":"488_CR17","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1038\/nature13194","volume":"508","author":"KV Huber","year":"2014","unstructured":"Huber KV, Salah E, Radic B, Gridling M, Elkins JM, Stukalov A, et al. Stereospecific targeting of MTH1 by (S)-crizotinib as an anticancer strategy. Nature. 2014;508:222\u20137.","journal-title":"Nature."},{"key":"488_CR18","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1016\/j.bmcl.2016.02.026","volume":"26","author":"A Petrocchi","year":"2016","unstructured":"Petrocchi A, Leo E, Reyna NJ, Hamilton MM, Shi X, Parker CA, et al. Identification of potent and selective MTH1 inhibitors. Bioorg Med Chem Lett. 2016;26:1503\u20137.","journal-title":"Bioorg Med Chem Lett"},{"key":"488_CR19","doi-asserted-by":"crossref","first-page":"3449","DOI":"10.1039\/C8SC05465G","volume":"10","author":"H Park","year":"2019","unstructured":"Park H, Park SB. Label-free target identification reveals oxidative DNA damage as the mechanism of a selective cytotoxic agent. Chem Sci. 2019;10:3449\u201358.","journal-title":"Chem Sci."},{"key":"488_CR20","volume":"5","author":"J Muller","year":"2014","unstructured":"Muller J, Krijgsman O, Tsoi J, Robert L, Hugo W, Song C, et al. Low MITF\/AXL ratio predicts early resistance to multiple targeted drugs in melanoma. Nat Commun. 2014;5:5712.","journal-title":"Nat Commun."},{"key":"488_CR21","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1038\/nature13121","volume":"508","author":"C Sun","year":"2014","unstructured":"Sun C, Wang L, Huang S, Heynen GJ, Prahallad A, Robert C, et al. Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma. Nature. 2014;508:118\u201322.","journal-title":"Nature."},{"key":"488_CR22","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1172\/JCI65780","volume":"123","author":"EV Abel","year":"2013","unstructured":"Abel EV, Basile KJ, Kugel CH 3rd, Witkiewicz AK, Le K, Amaravadi RK, et al. Melanoma adapts to RAF\/MEK inhibitors through FOXD3-mediated upregulation of ERBB3. J Clin Investig. 2013;123:2155\u201368.","journal-title":"J Clin Investig"},{"key":"488_CR23","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-017-02674-y","volume":"9","author":"M Werner-Klein","year":"2018","unstructured":"Werner-Klein M, Scheitler S, Hoffmann M, Hodak I, Dietz K, Lehnert P, et al. Genetic alterations driving metastatic colony formation are acquired outside of the primary tumour in melanoma. Nat Commun. 2018;9:595.","journal-title":"Nat Commun."},{"key":"488_CR24","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1158\/1541-7786.MCR-16-0157","volume":"15","author":"K Balaji","year":"2017","unstructured":"Balaji K, Vijayaraghavan S, Diao L, Tong P, Fan Y, Carey JP, et al. AXL inhibition suppresses the DNA damage response and sensitizes cells to PARP inhibition in multiple cancers. Mol Cancer Res. 2017;15:45\u201358.","journal-title":"Mol Cancer Res"},{"key":"488_CR25","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/978-1-4614-1222-9_3","volume":"729","author":"C Boscher","year":"2012","unstructured":"Boscher C, Nabi IR. Caveolin-1: role in cell signaling. Adv Exp Med Biol. 2012;729:29\u201350.","journal-title":"Adv Exp Med Biol"},{"key":"488_CR26","doi-asserted-by":"crossref","first-page":"e105278","DOI":"10.1371\/journal.pone.0105278","volume":"9","author":"P Korhan","year":"2014","unstructured":"Korhan P, Erdal E, Kandemis E, Cokakli M, Nart D, Yilmaz F, et al. Reciprocal activating crosstalk between c-Met and caveolin 1 promotes invasive phenotype in hepatocellular carcinoma. PLoS One. 2014;9:e105278.","journal-title":"PLoS One."},{"key":"488_CR27","doi-asserted-by":"crossref","DOI":"10.1038\/cddis.2017.406","volume":"8","author":"A Azimi","year":"2017","unstructured":"Azimi A, Tuominen R, Costa Svedman F, Caramuta S, Pernemalm M, Frostvik Stolt M, et al. Silencing FLI or targeting CD13\/ANPEP lead to dephosphorylation of EPHA2, a mediator of BRAF inhibitor resistance, and induce growth arrest or apoptosis in melanoma cells. Cell Death Dis. 2017;8:e3029.","journal-title":"Cell Death Dis"},{"key":"488_CR28","doi-asserted-by":"crossref","first-page":"2346","DOI":"10.1021\/acs.jmedchem.5b01760","volume":"59","author":"JG Kettle","year":"2016","unstructured":"Kettle JG, Alwan H, Bista M, Breed J, Davies NL, Eckersley K, et al. Potent and selective inhibitors of MTH1 probe its role in cancer cell survival. J Med Chem. 2016;59:2346\u201361.","journal-title":"J Med Chem"},{"key":"488_CR29","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1093\/neuonc\/noy071","volume":"20","author":"L Pudelko","year":"2018","unstructured":"Pudelko L, Edwards S, Balan M, Nyqvist D, Al-Saadi J, Dittmer J, et al. An orthotopic glioblastoma animal model suitable for high-throughput screenings. Neuro Oncol. 2018;20:1475\u201384.","journal-title":"Neuro Oncol"},{"key":"488_CR30","doi-asserted-by":"crossref","first-page":"e19713","DOI":"10.1371\/journal.pone.0019713","volume":"6","author":"D Inoue","year":"2011","unstructured":"Inoue D, Wittbrodt J. One for all\u2013a highly efficient and versatile method for fluorescent immunostaining in fish embryos. PLoS One. 2011;6:e19713.","journal-title":"PLoS One."},{"key":"488_CR31","doi-asserted-by":"crossref","first-page":"2275","DOI":"10.1093\/annonc\/mdw429","volume":"27","author":"U Warpman Berglund","year":"2016","unstructured":"Warpman Berglund U, Sanjiv K, Gad H, Kalderen C, Koolmeister T, Pham T, et al. Validation and development of MTH1 inhibitors for treatment of cancer. Ann Oncol. 2016;27:2275\u201383.","journal-title":"Ann Oncol."},{"key":"488_CR32","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1128\/MCB.23.5.1581-1589.2003","volume":"23","author":"GD Frank","year":"2003","unstructured":"Frank GD, Mifune M, Inagami T, Ohba M, Sasaki T, Higashiyama S, et al. Distinct mechanisms of receptor and nonreceptor tyrosine kinase activation by reactive oxygen species in vascular smooth muscle cells: role of metalloprotease and protein kinase C-delta. Mol Cell Biol. 2003;23:1581\u20139.","journal-title":"Mol Cell Biol"},{"key":"488_CR33","doi-asserted-by":"crossref","first-page":"3120","DOI":"10.1210\/endo.141.9.7630","volume":"141","author":"GD Frank","year":"2000","unstructured":"Frank GD, Eguchi S, Yamakawa T, Tanaka S, Inagami T, Motley ED. Involvement of reactive oxygen species in the activation of tyrosine kinase and extracellular signal-regulated kinase by angiotensin II. Endocrinology. 2000;141:3120\u20136.","journal-title":"Endocrinology."},{"key":"488_CR34","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1042\/CS20110411","volume":"122","author":"VA Korshunov","year":"2012","unstructured":"Korshunov VA. Axl-dependent signalling: a clinical update. Clin Sci. 2012;122:361\u20138.","journal-title":"Clin Sci"},{"key":"488_CR35","doi-asserted-by":"crossref","first-page":"2389523","DOI":"10.1155\/2018\/2389523","volume":"2018","author":"P Davalli","year":"2018","unstructured":"Davalli P, Marverti G, Lauriola A, D'Arca D. Targeting oxidatively induced DNA damage response in cancer: opportunities for novel cancer therapies. Oxid Med Cell Longev. 2018;2018:2389523.","journal-title":"Oxid Med Cell Longev"},{"key":"488_CR36","doi-asserted-by":"crossref","first-page":"2586","DOI":"10.1038\/onc.2014.195","volume":"34","author":"A Patel","year":"2015","unstructured":"Patel A, Burton DG, Halvorsen K, Balkan W, Reiner T, Perez-Stable C, et al. MutT homolog 1 (MTH1) maintains multiple KRAS-driven pro-malignant pathways. Oncogene. 2015;34:2586\u201396.","journal-title":"Oncogene."},{"key":"488_CR37","doi-asserted-by":"crossref","DOI":"10.1038\/s41419-018-0865-6","volume":"9","author":"BO Einarsdottir","year":"2018","unstructured":"Einarsdottir BO, Karlsson J, Soderberg EMV, Lindberg MF, Funck-Brentano E, Jespersen H, et al. A patient-derived xenograft pre-clinical trial reveals treatment responses and a resistance mechanism to karonudib in metastatic melanoma. Cell Death Dis. 2018;9:810.","journal-title":"Cell Death Dis"},{"key":"488_CR38","doi-asserted-by":"crossref","first-page":"21541","DOI":"10.1074\/jbc.M112.363010","volume":"287","author":"Y Takagi","year":"2012","unstructured":"Takagi Y, Setoyama D, Ito R, Kamiya H, Yamagata Y, Sekiguchi M. Human MTH3 (NUDT18) protein hydrolyzes oxidized forms of guanosine and deoxyguanosine diphosphates: comparison with MTH1 and MTH2. J Biol Chem. 2012;287:21541\u20139.","journal-title":"J Biol Chem"},{"key":"488_CR39","volume":"6","author":"T Kawamura","year":"2016","unstructured":"Kawamura T, Kawatani M, Muroi M, Kondoh Y, Futamura Y, Aono H, et al. Proteomic profiling of small-molecule inhibitors reveals dispensability of MTH1 for cancer cell survival. Sci Rep. 2016;6:26521.","journal-title":"Sci Rep."},{"key":"488_CR40","doi-asserted-by":"crossref","unstructured":"Gad H, Mortusewicz O, Rudd S, Stolz A, Amaral N, Brautigham L, et al. MTH1 promotes mitotic progression to avoid oxidative DNA damage in cancer cells. bioRxiv 2019: 575290.","DOI":"10.1101\/575290"},{"key":"488_CR41","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.cels.2019.05.009","volume":"9","author":"JC Patterson","year":"2019","unstructured":"Patterson JC, Joughin BA, Prota AE, Muhlethaler T, Jonas OH, Whitman MA, et al. VISAGE reveals a targetable mitotic spindle vulnerability in cancer cells. Cell Syst. 2019;9:74\u201392 e8.","journal-title":"Cell Syst"},{"key":"488_CR42","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms8871","volume":"6","author":"M Carter","year":"2015","unstructured":"Carter M, Jemth AS, Hagenkort A, Page BD, Gustafsson R, Griese JJ, et al. Crystal structure, biochemical and cellular activities demonstrate separate functions of MTH1 and MTH2. Nat Commun. 2015;6:7871.","journal-title":"Nat Commun."},{"key":"488_CR43","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.1074\/jbc.M117.815902","volume":"293","author":"D Volonte","year":"2018","unstructured":"Volonte D, Vyas AR, Chen C, Dacic S, Stabile LP, Kurland BF, et al. Caveolin-1 promotes the tumor suppressor properties of oncogene-induced cellular senescence. J Biol Chem. 2018;293:1794\u2013809.","journal-title":"J Biol Chem"},{"key":"488_CR44","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1038\/s41419-019-1875-8","volume":"10","author":"I Das","year":"2019","unstructured":"Das I, Wilhelm M, H\u00f6iom V, Franco Marquez R, Costa Svedman F, Hansson J, et al. Combining ERBB family and MET inhibitors is an effective therapeutic strategy in cutaneous malignant melanoma independent of BRAF\/NRAS mutation status. Cell Death Dis. 2019;10:663.","journal-title":"Cell Death Dis"}],"container-title":["Cell Death &amp; Differentiation"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41418-019-0488-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41418-019-0488-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41418-019-0488-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T21:14:47Z","timestamp":1684617287000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41418-019-0488-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1,9]]},"references-count":44,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2020,7]]}},"alternative-id":["488"],"URL":"https:\/\/doi.org\/10.1038\/s41418-019-0488-1","relation":{},"ISSN":["1350-9047","1476-5403"],"issn-type":[{"value":"1350-9047","type":"print"},{"value":"1476-5403","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,1,9]]},"assertion":[{"value":"15 July 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 December 2019","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 December 2019","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 January 2020","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"A patent has been filed with TH1579 where TH is listed as inventor. The Intellectual Property Right is owned by nonprofit Thomas Helleday Foundation for Medical Research (THF). TH, UWB, and HG are board members of the THF. THF is sponsor for on-going clinical trial with TH1579. Oxcia AB is assisting THF in TH1579 clinical trial and UWB is chairman of Oxcia AB and HG, IA, LB, LP, UWB, and TH are shareholders in Oxcia AB. The other authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}